drugset / Trial / NCT04627675
CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This is a Phase 1, open-label study to evaluate the safety profile of CORVax +/- pIL-12, (electroporated SARS-CoV-2 spike (S) protein plasmid DNA vaccine with or without the combination of electroporated IL-12p70 plasmid.
Timeline
- Start
- 2020-12-30
- Primary completion
- 2022-09-19
- Completion
- 2022-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CORVax | Vaccine | — | — |
| Subject | Tavokinogene Telseplasmid | Vaccine | — | — |